Medicine News and Research

RSS

New simple diagnostic tool to detect dangerous viruses

Boston University researchers have developed a simple diagnostic tool that can quickly identify dangerous viruses like Ebola and Marburg. The biosensor, which is the size of a quarter and can detect viruses in a blood sample, could be used in developing nations, airports and other places where natural or man-made outbreaks could erupt.

22 Nov 2010

UC San Diego designated as Blue Distinction Center

UC San Diego Health System has been designated as a Blue Distinction Center for Spine Surgery and a Blue Distinction Center for Knee and Hip Replacement. This honor is awarded to medical facilities that have demonstrated expertise in delivering quality health care in certain specialty medical areas by the Blue Cross and Blue Shield Association.

22 Nov 2010

State roundup: Calif. stem cell research; Mass. prisons change HIV medicine procedure; Native Americans' high suicide rates

When millionaire Silicon Valley real estate developer Bob Klein launched his ballot drive to create a $3-billion state fund for stem-cell research in 2004, he pitched it as a way of taking politics out of science and focusing on cures.

22 Nov 2010

Australian university students a ‘stressed out’ bunch: Study

According to the latest findings the rates of serious mental illness are more than five times higher among university students than in the general population. The study conducted by researchers at University of Queensland was published in the latest issue of Australian Psychologist. It also found that rate of pyschological distress among university students is almost three times higher than in the general population.

22 Nov 2010

The conservative way forward on health care

The landslide Republican victory, in taking the House and electing some strong conservatives to the Senate, can be interpreted as a mandate to rein in government spending, and specifically to repeal ObamaCare, as these issues were clearly behind the large turnout. There is still a very real possibility the Supreme Court will find the “individual mandate” to buy private insurance unconstitutional. If this provision is thrown out, it’s hard to see how the law survives, since the mandate is needed to finance it.

22 Nov 2010

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

22 Nov 2010

Research roundup: Health IT and malpractice; Wide variation in hospital rates; Income and insurance offerings

New England Journal of Medicine: Medical Malpractice Liability In The Age Of Electronic Health Records - "Providers can expect a varied and shifting landscape of medical liability risks and benefits as the adoption of [electronic health records] EHRs unfolds," write the authors who explore the ways EHRs may bring about long-term changes in standard of care and affect the course of malpractice litigation.

22 Nov 2010

Humana to acquire Concentra for $790 million

Humana Inc. today announced it has signed a definitive agreement to purchase Concentra Inc., a privately held health care company based in Addison, Texas, for approximately $790 million in cash. Through its affiliated clinicians, Concentra delivers occupational medicine, urgent care, physical therapy and wellness services to workers and the general public from more than 300 medical centers in 42 states.

22 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

Variation at gene locus associated with greater reproductive success

Since 1871, when Charles Darwin wrote The Descent of Man, it has been widely accepted that "Variability is the necessary basis for the action of selection." Variability is associated with the ability to adapt, which is clearly beneficial at a species level. But there is increasing evidence that genetic variability may also give rise to advantages at the level of the individual.

22 Nov 2010

Perspectives on World Health Report 2010

With the financial crisis still hanging over many countries, this year's World Health Report from the World Health Organization, "Health Systems Financing: The Path to Universal Coverage" is timely and relevant to the question of how to ensure that all people have access to health care services, without suffering financial hardship. This is the conclusion of a Perspective article on the 2010 World Health Report from Sara Bennett (Johns Hopkins University, USA) and colleagues, published in PLoS Medicine to coincide with the release of the Report.

22 Nov 2010

Military surgeons provide guidance on handling emergency blast injuries

Hospitals all over the world need to be aware of how to treat emergency blast injuries and military surgeons can provide valuable knowledge and advice to their civilian counterparts based on their experience of battlefield injuries. That is the driving force behind two papers published online by BJS, the British Journal of Surgery.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

22 Nov 2010

IVCC receives $50 million to develop new insecticides

The Innovative Vector Control Consortium has received $50 million from the Bill & Melinda Gates Foundation to continue its work to develop new insecticides for the improved control of mosquitoes and other insects which transmit malaria, dengue and other neglected tropical diseases.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Medicine News and Research

New simple diagnostic tool to detect dangerous viruses

UC San Diego designated as Blue Distinction Center

State roundup: Calif. stem cell research; Mass. prisons change HIV medicine procedure; Native Americans' high suicide rates

Australian university students a ‘stressed out’ bunch: Study

The conservative way forward on health care

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Research roundup: Health IT and malpractice; Wide variation in hospital rates; Income and insurance offerings

Humana to acquire Concentra for $790 million

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

Variation at gene locus associated with greater reproductive success

Perspectives on World Health Report 2010

Military surgeons provide guidance on handling emergency blast injuries

VYTORIN reduces major vascular events in patients with chronic kidney disease

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

IVCC receives $50 million to develop new insecticides

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News